A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

Background—H 2 receptor blockers and proton pump inhibitors reduce intestinal output in patients with short bowel syndrome. Aims—To evaluate the effect of intravenous omeprazole and ranitidine on ...